What is HC Wainwright’s Estimate for DVAX Q1 Earnings?

Dynavax Technologies Co. (NASDAQ:DVAX) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Dynavax Technologies in a report issued on Tuesday, January 14th. HC Wainwright analyst E. White expects that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter. HC Wainwright has a “Buy” rating and a $31.00 price objective on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share. HC Wainwright also issued estimates for Dynavax Technologies’ Q4 2025 earnings at $0.09 EPS and FY2027 earnings at $0.64 EPS.

Separately, StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th.

Dynavax Technologies Stock Up 0.5 %

DVAX opened at $12.45 on Friday. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of 95.78 and a beta of 1.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The firm’s 50-day simple moving average is $12.76 and its 200-day simple moving average is $11.68. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $14.30.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its holdings in Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,685 shares during the period. US Bancorp DE increased its position in shares of Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies during the third quarter worth $45,000. Nisa Investment Advisors LLC raised its holdings in shares of Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in Dynavax Technologies in the 3rd quarter valued at $89,000. 96.96% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.